ILLUMINA, INC. Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Business Resilience: Despite macroeconomic challenges, Q1 revenue and EPS were at the upper end of guidance. NovaSeq X instruments had over 60 placements in Q1, exceeding expectations.
• China Impact: Export restrictions on instruments led to lower revenue from the Greater China region in 2025. Actively engaging with Chinese regulators for a sustainable long-term presence.
• U.S. Research Funding: Uncertainty in research funding affected customers; offering flexible solutions to sustain research projects.
• Cost Reduction: Implemented a $100 million global cost reduction program, with savings realized in 2025. Took actions to address tariff impacts through supply chain optimization and pricing.
• Innovation Pipeline: Launched new spatial offering, single-cell CRISPR research solution, and other technologies in development, with products set for release in 2025-2026.

Segment Performance

• Sequencing Consumables: Revenue of $696 million, grew approximately 1% year-over-year. Contributed ~66.9% to total revenue. Driven by strong sequencing activity, especially from clinical customers.
• Sequencing Instruments: Revenue of $109 million, approximately flat year-over-year. Higher shipments of NovaSeq X series instruments in high throughput and successful launch of MiSeq i100. Contributed ~10.5% to total revenue.
• Sequencing Service and Other: Revenue of $142 million, down ~5% year-over-year. Mainly due to timing of certain strategic partnership revenues. Contributed ~13.7% to total revenue.

Guidance

• Revenue: Revised guidance for Greater China: $165M-$185M full-year. Rest of the world revenue expected to grow 1% midpoint, with research market constraints partially offset by clinical growth.
• EPS: Guidance range $4.20-$4.30, accounting for tariff impact and cost actions. Q2 revenue expected $1.04B-$1.06B, non-GAAP operating margin ~21%, EPS $1-$1.04.
• Product Assumptions: Excluding Greater China, sequencing consumables growth flat to 2%, sequencing instruments roughly flat year-over-year.

Risks

• China Export Restrictions: Continued impact on revenue due to restricted instrument exports to China.
• U.S. Research Funding Uncertainty: Affects customer purchasing timelines and research project progress.
• Tariffs: Increased costs from U.S. import tariffs, requiring supply chain optimization and pricing actions to mitigate impact.

Question and Answer

Q: On top line growth outlook, clinical vs research revenue growth?

A: Jacob and Ankur discussed clinical growth in mid-single digits, while research is expected to have a mid-double digit decline.

Q: Consumables in mid-throughput and low-throughput?

A: Mid-throughput challenged by macro factors; low-throughput MiSeq i100 well-received, but facing price rebalancing and competition issues.

Q: Tariff impact and revenue guide conservatism?

A: Jacob and Ankur discussed tariff offset actions and strong order bookings as performance obligations contributing to guide conservatism.

Q: Competitive front and customer equipment purchasing delay?

A: Jacob stated no significant disruption from competitors' new tech; customers value certainty of deliverables from Illumina.

Q: China and academic/government markets outlook?

A: Jacob and Ankur mentioned working with Chinese regulators for a resolution and academic/government headwinds seen as temporary.

Q: SEC investigation on GRAIL and acquisitions?

A: Ankur and Jacob discussed SEC investigation closure, focus on bolt-on acquisitions and cash flow generation from GRAIL divestiture.

Q: Tariff mitigation actions and EPS pacing?

A: Jacob discussed supply chain optimization, pricing actions, and half-year offset of tariff impact on EPS pacing.